Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) EBITDA (2019 - 2025)

Historic EBITDA for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$32.0 million.

  • C4 Therapeutics' EBITDA fell 3482.39% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.4 million, marking a year-over-year decrease of 1470.26%. This contributed to the annual value of -$105.1 million for FY2024, which is 1817.13% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' EBITDA is -$32.0 million, which was down 3482.39% from -$26.1 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' EBITDA ranged from a high of -$16.3 million in Q4 2021 and a low of -$35.9 million during Q4 2022
  • Over the past 5 years, C4 Therapeutics' median EBITDA value was -$28.3 million (recorded in 2022), while the average stood at -$28.1 million.
  • As far as peak fluctuations go, C4 Therapeutics' EBITDA crashed by 12062.29% in 2022, and later skyrocketed by 4953.73% in 2024.
  • Over the past 5 years, C4 Therapeutics' EBITDA (Quarter) stood at -$16.3 million in 2021, then plummeted by 120.62% to -$35.9 million in 2022, then rose by 5.39% to -$34.0 million in 2023, then decreased by 2.94% to -$35.0 million in 2024, then grew by 8.37% to -$32.0 million in 2025.
  • Its EBITDA stands at -$32.0 million for Q3 2025, versus -$26.1 million for Q2 2025 and -$26.3 million for Q1 2025.